{"id":54966,"date":"2023-03-18T22:03:03","date_gmt":"2023-03-18T21:03:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/"},"modified":"2023-03-18T22:03:03","modified_gmt":"2023-03-18T21:03:03","slug":"california-selects-civica-rx-as-its-insulin-manufacturing-partner","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/","title":{"rendered":"California Selects Civica Rx as Its Insulin Manufacturing Partner"},"content":{"rendered":"
\n

\nCalifornians with diabetes will have access to Civica\u2019s low-cost insulins via the CalRx Biosimilar Insulin Initiative<\/i>\n<\/p>\n

\nCalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens<\/i>\n<\/p>\n

LEHI, Utah–(BUSINESS WIRE)–Civica Inc. (Civica, Civica Rx) today announced it will manufacture insulins for the State of California\u2019s CalRx Biosimilar Insulin Initiative as part of its insulin manufacturing work. Once approved, Civica\u2019s biosimilar versions of the most commonly used short-and long-acting insulins will be available to Californians and nationwide at significantly lower prices than insulins currently on the market. The availability of these insulins will benefit Californians with diabetes who have been forced to choose between life sustaining medicines and living expenses.\n<\/p>\n

<\/a><\/p>\n

\n\u201cDiabetes has become an overwhelmingly expensive chronic condition, and it is heartbreaking that millions of people in California and across the U.S. are faced with the possibility of having to ration their care and put their lives at risk because they can no longer afford insulin<\/i>,\u201d said Ned McCoy, President and CEO of Civica. \u201cWe applaud California for its mission-driven commitment to lowering the cost of insulin and look forward to our groundbreaking partnership on behalf of people living with diabetes.<\/i>\u201d\n<\/p>\n

\nWith a significant $50 million dollar investment towards the development, manufacture and distribution of Civica\u2019s low-cost insulins<\/a>, California is stepping up to collaborate on this effort with partners that represent nearly every corner of the diabetes ecosystem, including the diabetes community, philanthropists, hospital systems, payers, clinical trial experts, drug substance manufacturers and leading pen and vial manufacturers. All partners are aligned with the goal of making low-cost insulins available to people living with diabetes.\n<\/p>\n

\n\u201cCalifornia\u2019s partnership with Civica is a game changer,\u201d said California Governor Gavin Newsom. \u201cWe are proud to be working with Civica to bring true price competition into the insulin drug market and ease the financial burden for Californians living with diabetes. Reducing the high cost of insulin is a critical step toward addressing health inequities and ensuring affordable and accessible health care for all.\u201d<\/i>\n<\/p>\n

\nCivica will produce three insulins \u2013 glargine, lispro and aspart (biologics corresponding to, and expected to be interchangeable with, Lantus, Humalog and Novolog, respectively) \u2013 each of which will be available both in vials and prefilled pens under the CalRx label. Civica and CalRx have the mutual goal of ensuring access to affordable insulins that have single, low transparent prices. As such, CalRx insulins manufactured by Civica are expected to have a manufacturer suggested retail price of no more than $30 per 10 mL vial and no more than $55 for a box of five 3 mL pre-filled pens, a significant discount to prices charged to uninsured individuals today.1<\/sup> At these prices, insured Californians who currently pay cost sharing amounts for their insulin will also experience overall savings.\n<\/p>\n

\nThe next phase of this partnership is assessing options for the standup of an insulin manufacturing facility in California and further efforts to disrupt the insulin market and provide additional benefits for patients who depend on this life saving drug.\n<\/p>\n

\nMore information on this initiative, including additional information on Civica\u2019s partners, can be found at https:\/\/civicainsulin.org<\/a>.\n<\/p>\n

\nAbout <\/b>Civica<\/b><\/a>\n<\/p>\n

\nCivica Inc. (Civica Rx, Civica) is a nonprofit, 501(c)(4) social welfare organization established in 2018 by health systems and philanthropies to increase the reliability of the drug supply chain, reduce drug shortages and related high prices in the United States. An experienced team of healthcare and pharmaceutical industry leaders is at the helm of the organization.\n<\/p>\n

\nToday, more than 55 health systems have joined Civica. They represent more than 1,550 hospitals and one-third of all U.S. hospital beds.\n<\/p>\n

\nTo lower the cost of medications for consumers at the pharmacy counter, Civica has created an outpatient entity, CivicaScript, in partnership with Blue Cross Blue Shield Association (BCBSA) and 18 Independent BCBS health plans, Elevance Health and other organizations focused on innovation in health care. CivicaScript recently launched its first medication for consumers \u2013 abiraterone acetate 250 mg \u2013 to help treat patients with prostate cancer.\n<\/p>\n

\nCivica\u2019s mission is to ensure that quality generic medications are accessible and affordable to everyone. From the beginning, the No. 1 Policy for the Civica family has been \u201cDo What Is in the Best Interest of Patients.\u201d\n<\/p>\n

\nCivica is building an essential medicines manufacturing facility in Petersburg, Virginia, to produce sterile injectable medications used in hospitals for patient care, emergency room and intensive-care unit treatments, surgeries, and to treat other serious conditions. This facility will manufacture insulin vials and prefilled pens for nationwide distribution, with manufacturing test runs expected to begin in late 2023.\n<\/p>\n

\nAbout CalRx<\/b>\n<\/p>\n

\nCalRx represents a groundbreaking solution for addressing drug affordability. Originally announced in January 2019 in Governor Newsom\u2019s first Executive Order and later signed into law in the California Affordable Drug Manufacturing Act of 2020 (Pan, SB 852, Chapter 207, Statutes of 2020), CalRx empowers the State of California to develop, produce, and distribute generic drugs and sell them at low cost.\n<\/p>\n

\nThe State will target prescription drugs where the pharmaceutical market has failed to lower drug costs, even when a generic or biosimilar medication is available.\n<\/p>\n

\nCompared to traditional procurement of prescription drugs, CalRx seeks deep, mutually beneficial partnerships with companies that share the State\u2019s goals.\n<\/p>\n

\n1<\/sup> Based on a publicly available current average list price of glargine (Lantus), lispro (Humalog) and aspart (Novolog) on https:\/\/www.goodrx.com\/<\/a> on February 28, 2022.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDebbi Ford
\n
(970) 227-3991
\n
Debbi.Ford@CivicaRx.org<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Californians with diabetes will have access to Civica\u2019s low-cost insulins via the CalRx Biosimilar Insulin Initiative CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens LEHI, Utah–(BUSINESS WIRE)–Civica Inc. (Civica, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54966","6":"format-standard","7":"category-industry"},"yoast_head":"\nCalifornia Selects Civica Rx as Its Insulin Manufacturing Partner - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"California Selects Civica Rx as Its Insulin Manufacturing Partner - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Californians with diabetes will have access to Civica\u2019s low-cost insulins via the CalRx Biosimilar Insulin Initiative CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens LEHI, Utah–(BUSINESS WIRE)–Civica Inc. (Civica, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-18T21:03:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230318005073\/en\/1741856\/21\/Civica_main_logo_with_R.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"California Selects Civica Rx as Its Insulin Manufacturing Partner\",\"datePublished\":\"2023-03-18T21:03:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/\"},\"wordCount\":916,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230318005073\\\/en\\\/1741856\\\/21\\\/Civica_main_logo_with_R.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/\",\"name\":\"California Selects Civica Rx as Its Insulin Manufacturing Partner - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230318005073\\\/en\\\/1741856\\\/21\\\/Civica_main_logo_with_R.jpg\",\"datePublished\":\"2023-03-18T21:03:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230318005073\\\/en\\\/1741856\\\/21\\\/Civica_main_logo_with_R.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230318005073\\\/en\\\/1741856\\\/21\\\/Civica_main_logo_with_R.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"California Selects Civica Rx as Its Insulin Manufacturing Partner\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"California Selects Civica Rx as Its Insulin Manufacturing Partner - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/","og_locale":"en_US","og_type":"article","og_title":"California Selects Civica Rx as Its Insulin Manufacturing Partner - Pharma Trend","og_description":"Californians with diabetes will have access to Civica\u2019s low-cost insulins via the CalRx Biosimilar Insulin Initiative CalRx will work with Civica to provide the most commonly used short- and long-acting insulins at planned prices of no more than $30 a vial and $55 for a box of five pre-filled pens LEHI, Utah–(BUSINESS WIRE)–Civica Inc. (Civica, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-18T21:03:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230318005073\/en\/1741856\/21\/Civica_main_logo_with_R.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"California Selects Civica Rx as Its Insulin Manufacturing Partner","datePublished":"2023-03-18T21:03:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/"},"wordCount":916,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230318005073\/en\/1741856\/21\/Civica_main_logo_with_R.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/","url":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/","name":"California Selects Civica Rx as Its Insulin Manufacturing Partner - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230318005073\/en\/1741856\/21\/Civica_main_logo_with_R.jpg","datePublished":"2023-03-18T21:03:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230318005073\/en\/1741856\/21\/Civica_main_logo_with_R.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230318005073\/en\/1741856\/21\/Civica_main_logo_with_R.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/california-selects-civica-rx-as-its-insulin-manufacturing-partner\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"California Selects Civica Rx as Its Insulin Manufacturing Partner"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54966"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54966\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}